Guardion Health Sciences (GHSI) 10-Q 10 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 10, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Entity Registrant Name	Guardion Health Sciences, Inc.
Entity Central Index Key	1,642,375
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		25,641,551

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets
Cash	$ 297,536	$ 62,520
Accounts receivable	1,662	1,673
Inventories	108,303	43,999
Current portion of deposits and prepaid expenses	6,576	29,363
Total current assets	414,077	137,555
Deposits and prepaid expenses, less current portion	10,470	10,470
Property and equipment, net	88,188	114,020
Total assets	512,735	262,045
Current liabilities
Accounts payable and accrued liabilities	413,907	356,467
Accrued expenses and deferred rent	14,667	88,290
Due to related parties	169,320	91,483
Convertible notes payable	45,811	44,323
Promissory notes payable	125,314	10,251
Promissory notes payable related party	0	16,805
Total current liabilities	769,019	607,619
Commitments and contingencies
Stockholders’ Deficiency
Common stock, $0.001 par value; 90,000,000 shares authorized; 25,634,751 and 25,046,438 shares issued and outstanding at June 30, 2017 and December 31, 2016	25,635	25,046
Additional paid-in capital	22,056,862	20,277,882
Accumulated deficit	(22,341,586)	(20,650,207)
Total stockholders’ deficiency	(256,284)	(345,574)
Total liabilities and stockholders’ deficiency	512,735	262,045
Series A Preferred Stock [Member]
Stockholders’ Deficiency
Preferred stock	1,705	1,705
Series B Preferred Stock [Member]
Stockholders’ Deficiency
Preferred stock	$ 1,100	$ 0

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	90,000,000	90,000,000
Common Stock, Shares, Issued	25,634,751	25,046,438
Common Stock, Shares, Outstanding	25,634,751	25,046,438
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	2,000,000	2,000,000
Preferred Stock, Shares Issued	1,705,154	1,705,154
Preferred Stock, Shares Outstanding	1,705,154	1,705,154
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001
Preferred Stock, Shares Authorized	2,000,000
Preferred Stock, Shares Issued	1,100,000
Preferred Stock, Shares Outstanding	1,100,000

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue	$ 59,977	$ 29,384	$ 115,912	$ 58,518
Cost of goods sold	29,692	12,883	52,326	27,130
Gross profit	30,285	16,501	63,586	31,388
Operating expenses
Research and development	15,530	12,101	25,770	22,273
Sales and marketing	101,598	104,535	178,333	208,114
General and administrative	766,894	893,045	1,365,807	1,517,002
Total operating expenses	884,022	1,009,681	1,569,910	1,747,389
Loss from operations	(853,737)	(993,180)	(1,506,324)	(1,716,001)
Other expenses:
Interest expense	1,924	357,446	18,355	583,830
Total other expenses	1,924	357,446	18,355	583,830
Net loss	(855,661)	(1,350,626)	(1,524,679)	(2,299,831)
Adjustments related to Series A and Series B convertible preferred stock:
Accretion of deemed dividend	(53,675)	(27,196)	(85,517)	(27,196)
Dividend declared	(45,106)	(1,664)	(81,183)	(1,664)
Net loss attributable to common shareholders	$ (954,442)	$ (1,379,486)	$ (1,691,379)	$ (2,328,691)
Net loss per common share - basic and diluted	$ (0.04)	$ (0.06)	$ (0.07)	$ (0.11)
Weighted average common shares outstanding - basic and diluted	25,470,418	21,315,242	25,287,759	21,299,171

Condensed Statement of Stockhol

Condensed Statement of Stockholders' Equity Deficiency - 6 months ended Jun. 30, 2017 - USD ($)	Total	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2016	$ (345,574)	$ 1,705	$ 0	$ 25,046	$ 20,277,882	$ (20,650,207)
Beginning Balance (in shares) at Dec. 31, 2016		1,705,154	0	25,046,438
Issuance of common stock for services	513,969	$ 0	$ 0	$ 458	513,511	0
Issuance of common stock for services (in shares)		0	0	457,500
Issuance of preferred stock	1,100,000	$ 0	$ 1,100	$ 0	1,098,900	0
Issuance of preferred stock (in shares)		0	1,100,000	0
Accretion of beneficial conversion feature on preferred stock	0			$ 0	85,517	(85,517)
Dividend on preferred stock	0	$ 0	$ 0	$ 131	81,052	(81,183)
Dividend on preferred stock (in shares)		0	0	130,813
Net loss	(1,524,679)	$ 0	$ 0	$ 0	0	(1,524,679)
Ending Balance at Jun. 30, 2017	$ (256,284)	$ 1,705	$ 1,100	$ 25,635	$ 22,056,862	$ (22,341,586)
Ending Balance (in shares) at Jun. 30, 2017		1,705,154	1,100,000	25,634,751

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating Activities
Net loss	$ (1,524,679)	$ (2,299,831)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	31,331	18,815
Amortization of debt discount	0	293,821
Accrued interest expense included in notes payable	13,746	40,827
Fair value of warrants issued as post-maturity interest	0	246,578
Stock-based compensation	405,918	378,056
Stock-based compensation - related parties	108,051	534,098
(Increase) decrease in -
Accounts receivable	11	329
Inventories	(64,305)	(3,295)
Deposits and prepaid expenses	22,788	17,358
Increase (decrease) in -
Accounts payable and accrued expenses	57,442	90,648
Accrued and deferred rent costs	(73,624)	(23,839)
Net cash used in operating activities	(1,023,321)	(706,435)
Investing Activities
Purchase of property and equipment	(5,500)	(1,171)
Net cash used in investing activities	(5,500)	(1,171)
Financing Activities
Proceeds from issuance of convertible notes payable	0	136,000
Proceeds from issuance of promissory notes - related party	0	140,000
Proceeds from issuance of promissory notes	100,000	170,000
Payments on promissory notes	(14,000)	(130,000)
Proceeds from issuance of preferred stock	1,100,000	545,000
Increase in due to related parties	77,837	110,300
Net cash provided by financing activities	1,263,837	971,300
Cash:
Net increase	235,016	263,694
Balance at beginning of period	62,520	13,850
Balance at end of period	297,536	277,544
Supplemental disclosure of cash flow information:
Cash paid for - Interest	1,500	0
Cash paid for - Income taxes	0	0
Non-cash financing activities:
Issuance of common stock dividends on preferred stock	81,183	1,664
Fair value of warrants issued in connection with promissory and convertible notes payable	0	245,349
Beneficial conversion feature associated with promissory and convertible notes payable	$ 0	$ 70,949

Organization and Business Opera

Organization and Business Operations	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Business Operations Organization and Business Guardion Health Sciences, Inc. (the “Company”) was formed in December 2009 as a California limited liability company under the name P4L Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc. The Company is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z ® Through June 30, 2017, the Company has had limited operations, but has been primarily engaged in research, development, commercialization and capital raising. The Company has incurred significant expenditures for the development of the Company's products and intellectual property, which includes research and development of both medical foods and medical diagnostic equipment for the treatment of various eye diseases. The Company had limited revenue during the six months ended June 30, 2017 and 2016, all of which was generated by the sale of the Company’s proprietary product, Lumega-Z. Going Concern and Liquidity The financial statements have been prepared assuming the Company will continue as a going concern. The Company had a net loss of $ 1,524,679 1,023,321 256,284 The Company’s independent registered public accounting firm has also included explanatory language in their report accompanying the Company’s audited financial statements for the year ended December 31, 2016 included in the 2016 Form 10-K that there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. The Company will continue to incur significant expenses for commercialization activities related to its lead product Lumega-Z, the MapcatSF medical device, and with respect to efforts to build the Company’s infrastructure. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of products other than Lumega-Z and the MapcatSF. The Company is continuing attempts to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include patent related costs and stock compensation expense, are expensed as incurred and totaled $ 25,770 22,273 Stock-Based Compensation The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers and directors, and to employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading market for its common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date. The Company has never declared or paid dividends on its common stock and has no plans to do so for the foreseeable future. The fair value of common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, the Company retained a third-party valuation firm whose input was utilized in determining the related per share valuations of the Company’s equity instruments. Management used valuations of $ 1.00 Six Months Ended June 30, 2017 2016 Discount rate 16 % 16 % Risk free rate 2.48 % 2.27 % Rate of return 16 % 16 % Sustainable growth rate 5 % 5 % Company survival probability 65 % 63 % Liquidation value $ 0 $ 0 Management considered business and market factors affecting the Company during the six-month periods ended June 30, 2017 and 2016, including capital raising efforts, proprietary technology, and other factors. Based on this evaluation, management believes that $ 0.88 1.00 The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB where the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The Company recognizes stock compensation expense on stock purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock over the price paid for the stock. The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises. The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants and shares of common stock issuable upon conversion of convertible debt and convertible preferred stock outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares of common stock issuable upon exercise of warrants and conversion of convertible debt and convertible preferred stock outstanding are anti-dilutive as they decrease loss per share. June 30, 2017 2016 Warrants 2,983,666 2,873,666 Estimated shares issuable upon conversion of convertible notes payable 31,250 1,445,811 Shares issuable upon conversion of convertible preferred stock 4,308,600 908,335 7,323,516 5,227,812 In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASB’s Exposure Draft Update issued on April 29, 2015, and approved in July 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, ASU 2014-09 is now effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation or disclosures. In July 2017, the FASB issued Accounting Standards Update No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The guidance in ASU 2017-11 is to be applied using a full or modified retrospective approach. The adoption of ASU 2017-11 is not currently expected to have any impact on the Company’s financial statement presentation or disclosures. The Company’s management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	3. Inventories Inventories consisted of the following: June 30, December 31, 2017 2016 Raw materials $ 106,159 $ 40,679 Finished goods 2,144 3,320 $ 108,303 $ 43,999

Property and Equipment, net

Property and Equipment, net	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	4. Property and Equipment, net Property and equipment consisted of the following: June 30, December 31, 2017 2016 Leasehold improvements $ 98,357 $ 98,357 Testing equipment 145,503 145,503 Furniture and fixtures 15,348 15,348 Computer equipment 15,277 15,277 Office equipment 8,193 2,694 282,678 277,179 Less accumulated depreciation and amortization (194,490) (163,159) $ 88,188 $ 114,020 For the six months ended June 30, 2017 and 2016, depreciation and amortization expense was $ 31,331 18,815 14,650 12,840 16,681 5,975

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Jun. 30, 2017
Convertible Notes Payable [Member]
Debt Disclosure [Text Block]	5. Convertible Notes Payable June 30, December 31, 2017 2016 Year of issuance: 2010 (due August 2013) $ 25,000 $ 25,000 Accrued interest 20,811 19,323 Notes payable $ 45,811 $ 44,323 In July 2010, the Company issued an unsecured convertible note payable in the amount of $ 25,000 12 0.08 20,811

Promissory Notes

Promissory Notes	6 Months Ended
	Jun. 30, 2017
Promissory Notes Payable [Member]
Debt Disclosure [Text Block]	6. Promissory Notes June 30, December 31, 2017 2016 Year of issuance: (a) 2016 (due November 2016) $ 10,000 $ 10,000 (b) 2017 (due May 2017) 100,000 - Accrued interest 15,314 251 Promissory notes payable, net $ 125,314 $ 10,251 (a) In 2016, the Company issued $ 170,000 4 9 10,000 449 251 (b) In January 2017, the Company issued a $ 100,000 120 6 0.75 8,000 13,040 822

Promissory Notes - Related Part

Promissory Notes - Related Party	6 Months Ended
	Jun. 30, 2017
Investor [Member]
Debt Disclosure [Text Block]	7. Promissory Notes – Related Party June 30, December 31, 2017 2016 Year of issuance: 2016 (due September 2016) $ - $ 14,000 Accrued interest - 2,805 Promissory notes payable – related party, net $ - $ 16,805 In 2016, the Company issued $ 140,000 6 12 14,000

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies The Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations in the normal course of business. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed financial statements at June 30, 2017 with respect to such matters, including the matter noted below. The Company recently received a payment demand from a former consultant to the Company alleging that he is owed approximately $ 192,000 On March 1, 2017, we entered into a non-binding letter of intent (“LOI”) with VectorVision, Inc., a Delaware corporation (“VectorVision”), whereby the parties set forth an outline of the terms and conditions pursuant to which we would acquire all of the outstanding shares of stock of VectorVision in exchange for a to be determined number of shares of our common stock. VectorVision specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. VectorVision’s patented standardization system is designed to provide the practitioner or researcher with the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. We believe the acquisition of VectorVision would expand our technical portfolio and further establish our position at the forefront of early detection, intervention and monitoring of a range of eye diseases. The transaction is subject to significant conditions precedent to closing, including, but not limited to, the satisfactory completion of due diligence, the determination of the amount of purchase consideration, the negotiation of definitive transaction documents, the completion of an audit of VectorVision’s financial statements, and other matters, no later than the August 31, 2017 expiration date of the LOI, as amended. No assurances can be provided regarding whether or when we may complete the acquisition of VectorVision. It is possible that we may never consummate this contemplated acquisition of VectorVision or we may complete such acquisition on terms materially different than those described herein.

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Stockholders’ Deficit Preferred Stock Series A During 2016, the Company sold 1,170,000 1.00 1,170,000 535,154 784,888 535,149 1.00 8 0.60 At the option of each holder, the Series A Preferred Stock (including accrued but unpaid dividends) may be converted into shares of the Company’s common stock commencing January 1, 2017 at $0.60 per share. The Series A Preferred Stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more. The issuance of the 1,170,000 shares of Series A Preferred Stock gave rise to a beneficial conversion feature due to the stated conversion price of $ 0.60 779,586 760,011 19,575 Sale of the Company’s Series A Preferred Stock was closed on December 31, 2016. During the six months ended June 30, 2017 the Company declared dividends of $ 67,646 112,759 Series B As of June 30, 2017, the Company had sold 1,100,000 1.00 1,100,000 1.00 6 0.75 0.75 The issuance of the Series B Preferred Stock gave rise to a beneficial conversion feature due to the stated conversion price of $0.75 per share being less than the market price of the shares at the issuance date. In addition, warrants were issued to purchasers of the Series B Preferred Stock who had previously participated in the 2016 Series A Preferred Stock offering. The Company accounted for the beneficial conversion feature, including an allocation of proceeds for the warrants on a relative fair value basis, in accordance with ASC 470-20, Accounting for Debt with Conversion and Other Options. The Company calculated a total deemed dividend on the Series B Preferred Stock of $ 234,840 65,942 During the six months ended June 30, 2017, the Company declared dividends of $ 13,537 18,054 Both classes of preferred stock will vote with the common stock on an “as converted” basis and have standard anti-dilution rights, exclusive of price protection. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, no distribution shall be made to the holders of any shares of common stock of the Company unless, prior thereto, the holders of all classes of preferred stock shall have received out of the available assets of the Company, whether capital or surplus, an amount equal to 100% of the stated value, plus any accrued and unpaid dividends thereon. If the assets of the Company are insufficient to pay in full such amounts due the holders of the preferred stock, then the entire assets shall be distributed ratably among the holders of the preferred stock, first to holders of Series A Preferred Stock, then to holders of Series B Preferred Stock, in accordance with the respective preferences and amounts that would be payable on such shares of preferred stock if all amounts payable thereon were paid in full. Preferred shareholders of both series have unlimited piggyback registration rights. Holders of a majority of the shares of preferred stock (based on the $1.00 stated value) outstanding shall have the right to one demand registration during the three (3) years following the effective date of the Company’s registration statement under the Securities Exchange Act of 1934, so long as at least $ 500,000 250,000 In the event of a merger or acquisition or change in control of the Company, both classes of preferred stock (including all accrued but unpaid dividends) will be deemed converted into shares of common stock immediately prior to the closing of such a transaction. Common Stock During 2016 and 2015, the Company issued 3,459,091 3,803,980 1,405,000 9 12 1,052,500 1,580,372 352,500 111,369 1,405,000 During the first six months of 2017, the Company issued 457,500 402,600 0.88 162,500 Weighted Average Grant Date Fair Number Value of Shares Per Share Non-vested, December 31, 2016 352,500 1.13 Issued 162,500 0.88 Vested (515,000) 1.05 Forfeited - - Non-vested, June 30, 2017 - $ - Warrants During March 2017, in connection with the Series B Preferred Stock offering discussed above, the Company issued a total of 60,000 0.75 51,796 0.88 135 1.61 Shares December 31, 2016 2,923,666 Granted 60,000 Forfeitures - Exercised - June 30, 2017, all exercisable 2,983,666 As of June 30, 2017, the Company had an aggregate of 2,983,666 0.37 1.4 1,293,512 0.88

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	10. Related Party Transactions Due to and from related parties represents unreimbursed expenses and compensation incurred on behalf of, and amounts loaned to the Company by, Michael Favish, the Company’s Chief Executive Officer, as well as other shareholders. The advances are unsecured, non-interest bearing and are due on demand. As of June 30, 2017 and December 31, 2016, the Company had $ 169,320 91,483 During the six months ended June 30, 2017, the Company incurred $ 125,000 50,000 250,000 48,500

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	11. Subsequent Events During July 2017, the Company issued 6,800 During July 2017, the Company issued 1,975,000 1,975,000 During July 2017, the Company repaid a $ 100,000

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis Of Presentation And Use Of Estimates Policy [Policy Text Block]	Basis of Presentation and Use of Estimates The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include patent related costs and stock compensation expense, are expensed as incurred and totaled $ 25,770 22,273
Compensation Related Costs, Policy [Policy Text Block]	Stock-Based Compensation The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers and directors, and to employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading market for its common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date. The Company has never declared or paid dividends on its common stock and has no plans to do so for the foreseeable future. The fair value of common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, the Company retained a third-party valuation firm whose input was utilized in determining the related per share valuations of the Company’s equity instruments. Management used valuations of $ 1.00 Six Months Ended June 30, 2017 2016 Discount rate 16 % 16 % Risk free rate 2.48 % 2.27 % Rate of return 16 % 16 % Sustainable growth rate 5 % 5 % Company survival probability 65 % 63 % Liquidation value $ 0 $ 0 Management considered business and market factors affecting the Company during the six-month periods ended June 30, 2017 and 2016, including capital raising efforts, proprietary technology, and other factors. Based on this evaluation, management believes that $ 0.88 1.00 The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB where the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The Company recognizes stock compensation expense on stock purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock over the price paid for the stock. The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants and shares of common stock issuable upon conversion of convertible debt and convertible preferred stock outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares of common stock issuable upon exercise of warrants and conversion of convertible debt and convertible preferred stock outstanding are anti-dilutive as they decrease loss per share. June 30, 2017 2016 Warrants 2,983,666 2,873,666 Estimated shares issuable upon conversion of convertible notes payable 31,250 1,445,811 Shares issuable upon conversion of convertible preferred stock 4,308,600 908,335 7,323,516 5,227,812
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASB’s Exposure Draft Update issued on April 29, 2015, and approved in July 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, ASU 2014-09 is now effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation or disclosures. In July 2017, the FASB issued Accounting Standards Update No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The guidance in ASU 2017-11 is to be applied using a full or modified retrospective approach. The adoption of ASU 2017-11 is not currently expected to have any impact on the Company’s financial statement presentation or disclosures. The Company’s management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions: Six Months Ended June 30, 2017 2016 Discount rate 16 % 16 % Risk free rate 2.48 % 2.27 % Rate of return 16 % 16 % Sustainable growth rate 5 % 5 % Company survival probability 65 % 63 % Liquidation value $ 0 $ 0
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: June 30, 2017 2016 Warrants 2,983,666 2,873,666 Estimated shares issuable upon conversion of convertible notes payable 31,250 1,445,811 Shares issuable upon conversion of convertible preferred stock 4,308,600 908,335 7,323,516 5,227,812

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories consisted of the following: June 30, December 31, 2017 2016 Raw materials $ 106,159 $ 40,679 Finished goods 2,144 3,320 $ 108,303 $ 43,999

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consisted of the following: June 30, December 31, 2017 2016 Leasehold improvements $ 98,357 $ 98,357 Testing equipment 145,503 145,503 Furniture and fixtures 15,348 15,348 Computer equipment 15,277 15,277 Office equipment 8,193 2,694 282,678 277,179 Less accumulated depreciation and amortization (194,490) (163,159) $ 88,188 $ 114,020

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2017
Convertible Notes Payable [Member]
Convertible Debt [Table Text Block]	June 30, December 31, 2017 2016 Year of issuance: 2010 (due August 2013) $ 25,000 $ 25,000 Accrued interest 20,811 19,323 Notes payable $ 45,811 $ 44,323

Promissory Notes (Tables)

Promissory Notes (Tables)	6 Months Ended
	Jun. 30, 2017
Promissory Notes Payable [Member]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	June 30, December 31, 2017 2016 Year of issuance: (a) 2016 (due November 2016) $ 10,000 $ 10,000 (b) 2017 (due May 2017) 100,000 - Accrued interest 15,314 251 Promissory notes payable, net $ 125,314 $ 10,251 (a) In 2016, the Company issued $ 170,000 4 9 10,000 449 251 (b) In January 2017, the Company issued a $ 100,000 120 6 0.75 8,000 13,040 822

Promissory Notes - Related Pa24

Promissory Notes - Related Party (Tables)	6 Months Ended
	Jun. 30, 2017
Investor [Member]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	June 30, December 31, 2017 2016 Year of issuance: 2016 (due September 2016) $ - $ 14,000 Accrued interest - 2,805 Promissory notes payable – related party, net $ - $ 16,805

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Nonvested Restricted Stock Shares Activity [Table Text Block]	Additional details of the Company’s restricted common stock are as follows: Weighted Average Grant Date Fair Number Value of Shares Per Share Non-vested, December 31, 2016 352,500 1.13 Issued 162,500 0.88 Vested (515,000) 1.05 Forfeited - - Non-vested, June 30, 2017 - $ -
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the Company’s warrant activity is as follows: Shares December 31, 2016 2,923,666 Granted 60,000 Forfeitures - Exercised - June 30, 2017, all exercisable 2,983,666

Organization and Business Ope26

Organization and Business Operations (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total			$ (1,023,321)	$ (706,435)
Stockholders' Equity Attributable to Parent, Total	$ 256,284		256,284
Net Income (Loss) Attributable to Parent, Total	$ (855,661)	$ (1,350,626)	$ (1,524,679)	$ (2,299,831)

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Discount rate	16.00%	16.00%
Risk free rate	2.48%	2.27%
Rate of return	16.00%	16.00%
Sustainable growth rate	5.00%	5.00%
Company survival probability	65.00%	63.00%
Liquidation value	$ 0	$ 0

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details 1) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,323,516	5,227,812
Conversion of Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,308,600	908,335
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	31,250	1,445,811
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,983,666	2,873,666

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016
Research and Development Expense	$ 15,530	$ 12,101	$ 25,770	$ 22,273
Share Price	$ 0.88	$ 1	$ 0.88	$ 1	$ 1

Inventories (Details)

Inventories (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Raw materials	$ 106,159	$ 40,679
Finished goods	2,144	3,320
Inventory, Net	$ 108,303	$ 43,999

Property and Equipment, net (De

Property and Equipment, net (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment, Gross, Total	$ 282,678	$ 277,179
Less accumulated depreciation and amortization	(194,490)	(163,159)
Property, Plant and Equipment, Net, Total	88,188	114,020
Office Equipment [Member]
Property, Plant and Equipment, Gross, Total	8,193	2,694
Computer Equipment [Member]
Property, Plant and Equipment, Gross, Total	15,277	15,277
Testing equipment [Member]
Property, Plant and Equipment, Gross, Total	145,503	145,503
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross, Total	98,357	98,357
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross, Total	$ 15,348	$ 15,348

Property and Equipment, net (32

Property and Equipment, net (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Depreciation, Depletion and Amortization, Nonproduction, Total			$ 31,331	$ 18,815
Research and Development Expense	$ 15,530	$ 12,101	25,770	22,273
General and Administrative Expense, Total	$ 766,894	$ 893,045	1,365,807	1,517,002
Property, Plant and Equipment [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total			31,331	18,815
Research and Development Expense			14,650	12,840
General and Administrative Expense, Total			$ 16,681	$ 5,975

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - Convertible Notes Payable [Member] - Unsecured Notes Payable [Member] - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Accrued interest	$ 20,811	$ 19,323
Notes payable	45,811	44,323
Due August 2013 [Member]
Debt Instrument, Face Amount	$ 25,000	$ 25,000

Convertible Notes Payable (De34

Convertible Notes Payable (Details Textual) - USD ($)	1 Months Ended	6 Months Ended
	Jul. 31, 2010	Jun. 30, 2017	Jun. 30, 2016
Proceeds from Convertible Debt		$ 0	$ 136,000
Convertible Notes Payable [Member] | Unsecured Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Debt Instrument, Convertible, Conversion Price	$ 0.08
Proceeds from Convertible Debt	$ 25,000
Interest Payable		$ 20,811

Promissory Notes (Details)

Promissory Notes (Details) - Notes Payable, Other Payables [Member] - USD ($)		Jun. 30, 2017	Dec. 31, 2016
Unsecured Promissory Notes [Member]
Accrued interest		$ 15,314	$ 251
Promissory notes payable, net		125,314	10,251
2016 (due November 2016)
Debt Instrument, Face Amount	[1]	10,000	10,000
2017 (due May 2017) [Member]
Debt Instrument, Face Amount	[2]	$ 100,000	$ 0
[1]	In 2016, the Company issued $170,000 of promissory notes to various outside investors, with simple interest rates ranging from 4% - 9% and a weighted average term at issuance of approximately three months. As of June 30, 2017 and December 31, 2016, a $10,000 note remained outstanding and was past due, and $449 and $251 of accrued interest is recorded as of June 30, 2017 and December 31, 2016.
[2]	In January 2017, the Company issued a $100,000 unsecured promissory note to an outside investor, with a term of 120 days and a fixed interest charge consisting of 6% of the principal in cash plus 6% of the principal in shares of common stock at a price of $0.75 per share, or 8,000 shares. Because the interest charge is fixed and due in full at any repayment date regardless of the stated maturity date, the Company recorded accrued interest of $13,040, representing the total fair value of the charge, at the inception of the note. As of June 30, 2017, this note is past due, and $822 of additional accrued interest has been recorded.

Promissory Notes (Details Textu

Promissory Notes (Details Textual) - USD ($)	1 Months Ended	6 Months Ended		12 Months Ended
	Jan. 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Mar. 31, 2017
Proceeds from Notes Payable		$ 100,000	$ 170,000
Short-term Debt					$ 14,000
2016 Issuances [Member]
Short-term Debt		10,000		$ 10,000
Interest Payable, Current		449		251
2016 Issuances [Member] | Investor [Member]
Proceeds from Notes Payable				140,000
Notes Payable, Other Payables [Member] | 2016 Issuances [Member]
Proceeds from Notes Payable				$ 170,000
Notes Payable, Other Payables [Member] | Minimum [Member] | 2016 Issuances [Member]
Debt Instrument, Interest Rate, Stated Percentage				4.00%
Notes Payable, Other Payables [Member] | Maximum [Member] | 2016 Issuances [Member]
Debt Instrument, Interest Rate, Stated Percentage				9.00%
Promissory Note [Member] | Investor [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.75
Interest Payable, Current	$ 13,040	$ 822
Debt Instrument, Face Amount	$ 100,000
Debt Instrument, Term	120 days
Short-term Debt, Percentage Bearing Fixed Interest Rate	6.00%
Debt Conversion, Converted Instrument, Shares Issued	8,000

Promissory Notes - Related Pa37

Promissory Notes - Related Party (Details) - Investor [Member] - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Accrued interest	$ 0	$ 2,805
Promissory notes payable - related party, net	0	16,805
2016 (due September 2016) [Member] | Unsecured Debt [Member]
Accrued interest	$ 0	$ 14,000

Promissory Notes - Related Pa38

Promissory Notes - Related Party (Details Textual) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Mar. 31, 2017
Proceeds from Notes Payable	$ 100,000	$ 170,000
Short-term Debt				$ 14,000
2016 Issuances [Member]
Short-term Debt	$ 10,000		$ 10,000
Minimum [Member] | Unsecured Debt [Member]
Fair Value Assumptions, Risk Free Interest Rate			6.00%
Maximum [Member] | Unsecured Debt [Member]
Fair Value Assumptions, Risk Free Interest Rate			12.00%
Investor [Member] | 2016 Issuances [Member]
Proceeds from Notes Payable			$ 140,000

Commitments and Contingencies (

Commitments and Contingencies (Details Textual)	6 Months Ended
	Jun. 30, 2017USD ($)
Loss Contingency, Damages Sought, Value	$ 192,000

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - Restricted Stock [Member]	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Number of Shares, Beginning Balance | shares	352,500
Number of Shares, Issued | shares	162,500
Number of Shares, Vested | shares	(515,000)
Number of Shares, Forfeited | shares	0
Number of Shares, Ending Balance | shares	0
Weighted Average Grant Date Fair Value Per Share, Beginning Balance | $ / shares	$ 1.13
Weighted Average Grant Date Fair Value Per Share, Issued | $ / shares	0.88
Weighted Average Grant Date Fair Value Per Share, Vested | $ / shares	1.05
Weighted Average Grant Date Fair Value Per Share, Forfeited | $ / shares	0
Weighted Average Grant Date Fair Value Per Share, Ending Balance | $ / shares	$ 0

Stockholders' Deficit (Details

Stockholders' Deficit (Details 1)	6 Months Ended
	Jun. 30, 2017shares
Class of Warrant or Right [Line Items]
Membership Units or Shares, Balance	2,923,666
Membership Units or Shares, Granted	60,000
Membership Units or Shares, Forfeitures	0
Membership Units or Shares, Exercised	0
Membership Units or Shares, Balance	2,983,666

Stockholders' Deficit (Detail42

Stockholders' Deficit (Details Textual) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Jan. 31, 2017	Sep. 30, 2016
Class of Warrant or Right [Line Items]
Shares Issued, Price Per Share	$ 1
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Class of Warrant or Right, Outstanding	2,983,666		2,923,666
Warrants Intrinsic Value	$ 1,293,512
Share Price	$ 0.88	$ 1			$ 1
Accretion of Dividends	$ 65,942		$ 760,011	$ 19,575
Debt Conversion, Original Debt, Amount			535,149
Stock Issued	81,183	$ 1,664
Warrants Issued	$ 60,000
Deemed Dividend			$ 779,586
Warrant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.37
Fair Value Assumptions, Expected Volatility Rate	135.00%
Fair Value Assumptions, Risk Free Interest Rate	1.61%
Warrants Weighted Average Remaining Life	1 year 4 months 24 days
Share Price	$ 0.88
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 51,796
Restricted Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, Issued for Services	457,500
Share Price	$ 0.88
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	162,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 1,405,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 402,600
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	0		352,500
Common Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues			3,459,091
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value			$ 111,369
Stock Issued			$ 3,803,980
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number			1,052,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value			$ 1,580,372
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number			1,405,000
Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			535,154
Stock Issued			$ 784,888
Minimum [Member]
Class of Warrant or Right [Line Items]
Accretion of Dividends	$ 250,000
Minimum [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period			9 months
Maximum [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period			12 months
Series A Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Shares Issued, Price Per Share			$ 1
Share Price			$ 1
Stock Issued During Period, Shares, New Issues			1,170,000
Stock Issued During Period, Value, New Issues			$ 1,170,000
Preferred Stock, Dividend Rate, Percentage			8.00%
Preferred Stock, Dividends Per Share, Declared	$ 0.60		$ 0.60
Convertible Preferred Stock, Terms of Conversion			The Series A Preferred Stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more.
Common Stock Dividends, Shares	112,759
Dividends, Preferred Stock, Stock	$ 67,646
Series A Preferred Stock [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Value, New Issues	$ 500,000
Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Share Price	$ 1
Stock Issued During Period, Shares, New Issues	1,100,000
Stock Issued During Period, Value, New Issues	$ 1,100,000
Preferred Stock, Dividend Rate, Percentage	6.00%
Preferred Stock, Dividends Per Share, Declared	$ 0.75
Convertible Preferred Stock, Conversion Price	$ 0.75
Convertible Preferred Stock, Terms of Conversion	The stock is automatically convertible by the Company upon an equity financing of at least $5,000,000 subsequent to June 30, 2017, or in the event the Company’s common stock is publicly traded for at least $2.00 per share for 10 consecutive trading days, or upon completion of a Major Transaction (as defined in the Certificate of Designation).
Common Stock Dividends, Shares	18,054
Deemed Dividend	$ 234,840
Series B Preferred Stock [Member] | Dividend Declared [Member]
Class of Warrant or Right [Line Items]
Dividends, Preferred Stock, Stock	$ 13,537

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Due to Related Parties, Current	$ 169,320	$ 91,483
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Payments to Employees	50,000	48,500
General and Administrative Expense [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Officers' Compensation	$ 125,000	$ 250,000

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	1 Months Ended	6 Months Ended
	Jul. 31, 2017	Jun. 30, 2017
Subsequent Event [Line Items]
Repayments of Related Party Debt	$ 100,000
Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		1,100,000
Stock Issued During Period, Value, New Issues		$ 1,100,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services	6,800
Subsequent Event [Member] | Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	1,975,000
Stock Issued During Period, Value, New Issues	$ 1,975,000